Laboratorios Farmaceuticos Rovi

ROVI · BME · EUR

57,80 €Veränderung zum vorherigen Schlusskurs: +0,78 %Absolute Veränderung: +0,45 €

Schlusskurs · 2. Oktober 2026

Unternehmensprofil

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche
Gesundheit
Industrie
Drug Manufacturers - Specialty & Generic
Hauptsitz
Calle José Isbert, 2, 28223, Pozuelo de Alarcón
Mitarbeitende
2.470
Notierung
ROVI · BME
Indizes
IBEX 35
Währung
EUR
ISIN
ES0157261019
Website
rovi.es